Sendur Neslihan, Karaman Göksun, Saniç Nagehan, Savk Ekin
Department of Dermatology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey.
J Dermatolog Treat. 2006;17(6):338-42. doi: 10.1080/09546630601028711.
The purpose of this study was to assess the efficacy of pimecrolimus cream 1% in vitiligo and to evaluate the effects of age of the patients, age of onset and duration of disease on response rate.
Twenty-three patients with vitiligo were enrolled in our study; 19 patients (seven male, 12 female) completed the 6-month study period. Patients were treated with topical pimecrolimus 1% cream once daily. The response was evaluated as excellent (76-100%), moderate (51-75%), mild (26-50%), minimal (1-25%), or no response.
The mean age of the 19 patients was 29.3+/-16.6 (range 7-62 years) and the mean duration of vitiligo was 68.4+/-81.3 months. Three patients demonstrated an excellent response to the therapy. Four patients had moderate, six patients had mild and five patients had minimal responses; one patient had no response to the treatment. Side effects were noted as a burning and stinging sensation in only three patients. The correlations between response rate and duration of the disease (r = 0.02, p = 0.95), onset age (r = -0.17, p = 0.48), and age of the patients (r = -0.16, p = 0.53) were not significant.
Pimecrolimus has a mild therapeutic effect on vitiligo without significant side effects and can be an alternative therapy agent.
本研究旨在评估1%吡美莫司乳膏治疗白癜风的疗效，并评估患者年龄、发病年龄和病程对有效率的影响。
23例白癜风患者纳入本研究；19例患者（7例男性，12例女性）完成了6个月的研究期。患者每日外用1%吡美莫司乳膏一次。疗效评估为优（76%-100%）、中（51%-75%）、轻（26%-50%）、微（1%-25%）或无效。
19例患者的平均年龄为29.3±16.6岁（范围7-62岁），白癜风平均病程为68.4±81.3个月。3例患者对治疗表现出优效反应。4例患者为中效，6例患者为低效，5例患者为微效；1例患者治疗无效。仅3例患者出现烧灼感和刺痛感等副作用。有效率与病程（r = 0.02，p = 0.95）、发病年龄（r = -0.17，p = 0.48）和患者年龄（r = -0.16，p = 0.53）之间的相关性不显著。
吡美莫司对白癜风有轻度治疗作用，且副作用不明显，可作为一种替代治疗药物。
